Novartis Ventures, Sweden’s HealthCap, France’s Truffle Capital and London Technology Fund, have participated in a £8.65m funding round for British biotech company Immune Targeting Systems (ITS).
Noerr’s Holger Ebersberger and Latham & Watkins’ Hanno Witt to join the firm’s Munich office
London-headquartered GP invested in AI provider MIcompany in first deal for new strategy this week
VC firm aims to raise USD 75m-150m from private and public investors including blue-chip institutional LPs in Europe, MENA and US
More than twice the size of its 2019 predecessor, the vehicle will allow for larger equity tickets, more investments and bolt-ons